OphtiMed Rx
Dana Rabinovich is the Co-Founder and CEO of OphtiMedRx, a pre-clinical drug development startup focused on developing molecular therapy for dry Age-related Macular Degeneration (AMD). Prior to this role, Dana was the owner of DR Biotech - Consulting and held positions such as Project Leader at Mor Research Applications, VP R&D at OmeCare, and Senior Project Manager at Salzman Group. With a background in Molecular Neuroscience (Ph.D.) and Molecular Genetics (M.Sc.), Dana has also served as a Research Director at GGA - Galil Genetic Analysis and as a Postdoctoral Fellow at the Weizmann Institute of Science. Additionally, Dana has experience mentoring students at the Davidson Institute of Science Education.
This person is not in any teams
OphtiMed Rx
OphtiMed Rx LTD is an ophthalmic drug development company, led by a team of physicians, scientists, and molecular biology experts. The company is developing a novel molecular therapy for dry Age-related Macular Degeneration (AMD), a common eye disease leading to blindness. This treatment protects retinal cells from senescence (cellular aging) and can halt progression of dry AMD. Our cutting-edge therapy will prevent the loss of vision and independence and bring enormous benefit to patients.